Featured

Commercial Excellence Summit Brings Together Leading Minds to Solve Critical Commercial Problems

This week is set to be a pivotal one in the life sciences industry. Leading minds in the field are coming together...

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

Amgen’s KRAS drug gets early FDA approval for lung cancer with specific mutation

On Friday, the United States FDA (Food and Drug Administration) has authorized a medication of Amgen Biopharmaceutical in patients with NSCLC

Roche is the biggest R&D spender investing 23.8% of its total sales

Last year, the research and development expenditures have been increased by 11% to $86.3 billion by the 11 top pharmaceutical companies of the world.

Bristol-Myers Squibb and Agenus enter a $1.56bn definitive agreement to support cancer programme

An exclusive international license contract of $1.56 billion has been signed between BMS (Bristol Myers Squibb) and Agenus, for AGEN1777

Sanofi accused of widespread employee email deletion tied to its 2019 recall of Zantac

Following FDA investigations on a contaminant suspected of causing cancer, Zantac, a renowned medication for acid reflux

Most life sciences executives say digital delivery of drugs is the future of health

The world’s leading connectivity and provider of electronic solutions, Molex and, its medical device distribution subsidiary, Phillips-Mediaize,

Latest news

Novo Nordisk Set to Slash Victoza Production to Boost Ozempic Supply

In response to the escalating demand for its GLP-1 weight loss products, Novo Nordisk is adopting a...

Merck to Purchase Caraway Therapeutics For Over $600M

Merck & Co. has openly expressed its continuous pursuit of acquisitions, and currently, the prominent pharmaceutical company...

NanoString Faces Setback in Patent Infringement Case Against Genomics

In a recent legal skirmish in the biotechnology sector, NanoString finds itself on the losing end of...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you

Provention gets FDA approval on diabetes medication after 35 years

When the FDA approved Provention Bio's Tzield...